FAKTOR-OPTIONSSCHEIN - INCYTE CO. | Market Closed - Börse Stuttgart 19:52:32 21/06/2024 BST | ||
| 2.81 EUR | +1.08% |
|
| Current month | -43.80% | ||
| 1 month | -45.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 2.81 | +1.08% |
| 20/06/24 | 2.78 | -14.46% |
| 19/06/24 | 3.25 | +4.84% |
| 18/06/24 | 3.1 | +6.16% |
| 17/06/24 | 2.92 | -2.34% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 07:52 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MG3VMR |
| ISIN | DE000MG3VMR6 |
| Date issued | 08/05/2024 |
| Strike | 72.76 $ |
| Maturity | Unlimited |
| Parity | 3.36 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.59 € |
|---|---|
| Lowest since issue | 2.74 € |
| Spread | 0.02 € |
| Spread % | 0.75% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
63.22
USD
Average target price
72.8
USD
Spread / Average Target
+15.15%
- Stock Market
- Certificates
- Certificat
